Research Project

Project Title:	A randomized, multicenter, double-blind, parallel, active-control study of the effects of Sparsentan, a dual endothelin receptor and angiotensin receptor blocker, on renal outcomes in patients with primary focal segmental glomerulosclerosis (DUPLEX)
Project Type:	Clinical Trial, Enrolment ongoing Adjunct biobank: Serum, Plasma, Urine
Disease group(s):	Immune glomerulopathies
Project Summary:	To determine the long-term nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with primary and genetic focal segmental glomerulosclerosis (FSGS).
Lead principal investigator(s):	William Morello, Milan
Project Period:	09/2018 - 09/2050
Sponsors:	Industry
Project web page:	https://www.orpha.net/en/research-trials/clinical-trial/659051?name=&mode=&country=&recruiting=0&terminated=0
ClinicalTrials.gov:	NCT03493685
EudraCT Nr.:	2016-00514123